Kaohsiung Medical University, Taiwan
Posters & Accepted Abstracts: J Cancer Sci Ther
Food and Drug Administration (FDA, USA) has approved the PEGylated technology that can be used in clinical treatment. With the times, numbers of PEGylated molecule has entered to clinical use, such as protein, liposome and small molecule. In previous study, we have established an anti-PEG sandwich ELISA (AGP4/3-3-Biotin) that can quantify the PEGylated compounds. However, the sensitivity of this PEG quantification platform might be affected that depend on the different kinds of the PEGylated molecules. In this study, we established an anti-PEG sandwich ELISA according to different combination of the high affinity anti-PEG antibodies that can provide extensive quantification to any kind of PEGylated compound.
Ming-yang Tseng received his Bachelor of Science Degree from I-Shou University, with a major in Biomedical Engineering. He completed Master’s degree from Kaohsiung Medical University and PhD degree at the Graduate Institute of Medicine in Kaohsiung Medical University. He is working on the characterization and development of antibodies in the laboratory of Dr. Tian-Lu Cheng.
Email: [email protected]